Clinically, GLP-1RAssuch as exenatide, liraglutide, dulaglutide, semaglutide, and tirzepatideare used to manage T2DM, mimicking endogenous GLP-1 activity
That places BPC-157 in the same regulatory bucket as other unapproved research peptides like TB-500 (thymosin beta-4 fragment) and GHK-Cu
Eating protein and fat before carbohydrates produces greater GLP-1 secretion than eating carbohydrates first
Together, we can protect the future of alternative treatments in California
However, the exact timing and intensity vary widely among individuals
In the Phase 3 TRIUMPH-4 trial, participants on the highest dose (12 mg) lost an average of 28.7% of their body weight over 68 weeks